Gulliver Biomed

Gulliver Biomed is a Belgian biotechnology company founded in 2018 as a UGent/VUB spin-off. The company specializes in the development and provision of camelid single-domain antibodies, also known as VHHs or Nanobodies. These high-quality, recombinant biological tools are engineered to be significantly smaller than conventional antibodies, which facilitates advanced bio-engineering, custom adaptation, and improved reproducibility in research and diagnostic applications. Their technological expertise is rooted in established academic research, and they offer a range of products including recombinant VHHs, Manduhai nanobodies, and custom antibody development services for the scientific community and private industry.

By providing these versatile tools, Gulliver Biomed supports researchers and partners across sectors such as biomedicine, biophysics, pharmaceuticals, and (medical) imaging. The company addresses common challenges in antibody research, such as reproducibility, by ensuring cDNA and protein sequences are readily available. Their products and custom services are designed to assist in a broad range of in vitro and in vivo applications, enabling clients to integrate these sophisticated biologicals into their specific research workflows to accelerate discovery and development.